Live feed15:00:00·950dPRReleasevia QuantisnowCelldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg BarzolvolimabByQuantisnow·Wall Street's wire, on your screen.CLDX· Celldex Therapeutics Inc.Health Care
